Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recommendations for genetic testing to reduce the incidence of anthracycline‐induced cardiotoxicity
Folefac Aminkeng, Colin J.D. Ross, Shahrad R. Rassekh, et al.
British Journal of Clinical Pharmacology (2016) Vol. 82, Iss. 3, pp. 683-695
Open Access | Times Cited: 210

Showing 1-25 of 210 citing articles:

Cardiovascular Complications of Cancer Therapy
Hui‐Ming Chang, Rohit Moudgil, Tiziano M. Scarabelli, et al.
Journal of the American College of Cardiology (2017) Vol. 70, Iss. 20, pp. 2536-2551
Open Access | Times Cited: 340
Hair cortisol analysis: An update on methodological considerations and clinical applications
Michael Greff, Jeffrey M. Levine, Awatif M. Abuzgaia, et al.
Clinical Biochemistry (2018) Vol. 63, pp. 1-9
Closed Access | Times Cited: 214
Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines
H. Abdullah-Koolmees, Antonius M. van Keulen, Marga Nijenhuis, et al.
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 163
Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group
Matthew J. Ehrhardt, Jan M. Leerink, Renée L. Mulder, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 3, pp. e108-e120
Closed Access | Times Cited: 70
Anthracycline Cardiotoxicity in Adult Cancer Patients
Massimiliano Camilli, Carlo M. Cipolla, Susan Dent, et al.
JACC CardioOncology (2024) Vol. 6, Iss. 5, pp. 655-677
Open Access | Times Cited: 19
Using Zebrafish for Investigating the Molecular Mechanisms of Drug-Induced Cardiotoxicity
Zain Zaki Zakaria, Fatiha M. Benslimane, Gheyath K. Nasrallah, et al.
BioMed Research International (2018) Vol. 2018, pp. 1-10
Open Access | Times Cited: 115
Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity
Volker M. Lauschke, Yitian Zhou, Magnus Ingelman‐Sundberg
Pharmacology & Therapeutics (2019) Vol. 197, pp. 122-152
Open Access | Times Cited: 113
Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment
Eric J. Chow, Kasey J. Leger, Neel S. Bhatt, et al.
Cardiovascular Research (2019) Vol. 115, Iss. 5, pp. 922-934
Open Access | Times Cited: 101
Pharmacogenomic Testing: Clinical Evidence and Implementation Challenges
Catriona Hippman, Corey Nislow
Journal of Personalized Medicine (2019) Vol. 9, Iss. 3, pp. 40-40
Open Access | Times Cited: 85
Cardiac Disease in Childhood Cancer Survivors
Jan M. Leerink, Esmée C. de Baat, Elizabeth A. M. Feijen, et al.
JACC CardioOncology (2020) Vol. 2, Iss. 3, pp. 363-378
Open Access | Times Cited: 71
Research progress of therapeutic drugs for doxorubicin-induced cardiomyopathy
Ye Chen‐Izu, Saixian Shi, Yan Dai
Biomedicine & Pharmacotherapy (2022) Vol. 156, pp. 113903-113903
Open Access | Times Cited: 68
Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy
Yu. A. Vasyuk, G. E. Gendlin, Е. И. Емелина, et al.
Russian Journal of Cardiology (2021) Vol. 26, Iss. 9, pp. 4703-4703
Open Access | Times Cited: 62
Chemotherapy-Related Cardiac Dysfunction
Marijke Linschoten, Arco J. Teske, Maarten J. Cramer, et al.
Circulation Genomic and Precision Medicine (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 78
Chemotherapy-induced cardiotoxicity in children
Neha Bansal, Shahnawaz Amdani, Emma R. Lipshultz, et al.
Expert Opinion on Drug Metabolism & Toxicology (2017) Vol. 13, Iss. 8, pp. 817-832
Closed Access | Times Cited: 72
RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy
Tarek Magdy, Zhengxin Jiang, Mariam Jouni, et al.
Cell stem cell (2021) Vol. 28, Iss. 12, pp. 2076-2089.e7
Open Access | Times Cited: 55
Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity
Tarek Magdy, Mariam Jouni, Hui–Hsuan Kuo, et al.
Circulation (2021) Vol. 145, Iss. 4, pp. 279-294
Open Access | Times Cited: 53
Molecular mechanisms of anthracycline cardiovascular toxicity
Anna Narezkina, Hari K. Narayan, Alice E. Zemljic‐Harpf
Clinical Science (2021) Vol. 135, Iss. 10, pp. 1311-1332
Closed Access | Times Cited: 43
Cardiotoxic Effect of Modern Anthracycline Dosing on Left Ventricular Ejection Fraction: A Systematic Review and Meta‐Analysis of Placebo Arms From Randomized Controlled Trials
Prajith Jeyaprakash, Sukhmandeep Sangha, K. Ellenberger, et al.
Journal of the American Heart Association (2021) Vol. 10, Iss. 6
Open Access | Times Cited: 42
Novel molecular mechanisms of doxorubicin cardiotoxicity: latest leading-edge advances and clinical implications
Y. Robert Li, Kassim Traore, Hong Zhu
Molecular and Cellular Biochemistry (2023) Vol. 479, Iss. 5, pp. 1121-1132
Closed Access | Times Cited: 16
Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial
Daniel Serie, Julia E. Crook, Brian M. Necela, et al.
Pharmacogenetics and Genomics (2017) Vol. 27, Iss. 10, pp. 378-385
Open Access | Times Cited: 58
Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity
Vivian Y. Chang, Jessica Wang
Current Oncology Reports (2018) Vol. 20, Iss. 7
Open Access | Times Cited: 56
Cardiovascular disease in survivors of childhood cancer
Neha Bansal, Shahnawaz M. Amdani, Kelley K. Hutchins, et al.
Current Opinion in Pediatrics (2018) Vol. 30, Iss. 5, pp. 628-638
Closed Access | Times Cited: 54
Subclinical Cardiac Dysfunction in Childhood Cancer Survivors on 10-Years Follow-Up Correlates With Cumulative Anthracycline Dose and Is Best Detected by Cardiopulmonary Exercise Testing, Circulating Serum Biomarker, Speckle Tracking Echocardiography, and Tissue Doppler Imaging
Cordula M. Wolf, Barbara Reiner, Andreas Kühn, et al.
Frontiers in Pediatrics (2020) Vol. 8
Open Access | Times Cited: 45
Challenges and Opportunities in Implementing Pharmacogenetic Testing in Clinical Settings
Wan‐Chun Chang, Reo Tanoshima, Colin J.D. Ross, et al.
The Annual Review of Pharmacology and Toxicology (2020) Vol. 61, Iss. 1, pp. 65-84
Open Access | Times Cited: 42
Page 1 - Next Page

Scroll to top